Journal Watch · European Heart Journal · 2026

Adverse pregnancy outcomes in successive pregnancies and maternal cardiovascular mortality: a Norwegian nationwide study.

Similar patterns were observed across individual APOs.<h4>Conclusions</h4>Considering APO sequence across complete pregnancy histories provides more detailed CVD information than binary classification.

Singh A, Skjærven R, Wilcox AJ et al.European Heart Journal3 min readPharma relevance 40/100

DOI: 10.1093/eurheartj/ehag564PMID: 42554048Study type: cohort / observational clinical study

TL;DR

Similar patterns were observed across individual APOs.<h4>Conclusions</h4>Considering APO sequence across complete pregnancy histories provides more detailed CVD information than binary classification.

Key findings

  • Binary classification indicated an overall 1.73-fold higher CVD mortality (95% CI 1.64-1.84).
  • Similar patterns were observed across individual APOs.<h4>Conclusions</h4>Considering APO sequence across complete pregnancy histories provides more detailed CVD information than binary classification.

Numbers at a glance (from the abstract)

95%1.73-fold

Every figure above is taken verbatim from the abstract below. Check the full text for denominators, confidence intervals and subgroup detail.

What they did

Hazard ratios (HRs) were estimated using Cox proportional hazards models.<h4>Results</h4>For composite APOs, women with APOs in first pregnancy and no further pregnancies had the highest CVD mortality [adjusted HR (aHR) 3.30, 95% confidence interval (CI) 2.97-3.66], followed by those with APOs in both first and later pregnancies (aHR 2.41, 95% CI 2.16-2.69). Women with APOs in later pregnancies only (aHR 1.65, 95% CI 1.50-1.81) and women with only one pregnancy without complications (aHR 1.83, 95% CI 1.69-1.97) had moderate CVD mortality. Women with APOs in first pregnancy followed by uncomplicated pregnancies (aHR 1.39, 95% CI 1.27-1.53) had the lowest CVD mortality.

Full abstract (original)

Background: <h4>Background and aims</h4>Binary classification of adverse pregnancy outcomes (APOs) may obscure differences in women's long-term cardiovascular disease (CVD) mortality. CVD mortality was therefore evaluated considering APO sequence and lifetime parity.<h4>Methods</h4>A total of 1 001 409 women with complete pregnancy histories were identified from the Medical Birth Registry of Norway (1967-2020) and linked to the Norwegian Cause of Death Registry for premature CVD mortality (≤70 years). Pregnancy histories were categorized by lifetime parity (1 vs ≥2) and APO sequence (first vs later) for composite APO, and APO recurrence type (same vs different) for individual APOs-preeclampsia, gestational hypertension, preterm delivery, perinatal loss, small for gestational age, placental abruption-multiparous women without APOs as reference, compared with binary classification (APO presence vs absence).

What they did: Hazard ratios (HRs) were estimated using Cox proportional hazards models.<h4>Results</h4>For composite APOs, women with APOs in first pregnancy and no further pregnancies had the highest CVD mortality [adjusted HR (aHR) 3.30, 95% confidence interval (CI) 2.97-3.66], followed by those with APOs in both first and later pregnancies (aHR 2.41, 95% CI 2.16-2.69). Women with APOs in later pregnancies only (aHR 1.65, 95% CI 1.50-1.81) and women with only one pregnancy without complications (aHR 1.83, 95% CI 1.69-1.97) had moderate CVD mortality. Women with APOs in first pregnancy followed by uncomplicated pregnancies (aHR 1.39, 95% CI 1.27-1.53) had the lowest CVD mortality.

Results & conclusions: Binary classification indicated an overall 1.73-fold higher CVD mortality (95% CI 1.64-1.84). Similar patterns were observed across individual APOs.<h4>Conclusions</h4>Considering APO sequence across complete pregnancy histories provides more detailed CVD information than binary classification.

Abstract © the authors / European Heart Journal (2026). Reproduced here for discussion and indexing, with attribution. Read the original at https://doi.org/10.1093/eurheartj/ehag564 · PubMed 42554048.

Why it matters for pharma & biotech

  • Relevant to Pharmacology & Drug Discovery teams tracking European Heart Journal for new targets, mechanisms and biomarkers.
  • As earlier-stage work, its near-term value is target validation and assay design rather than clinical decisions.
  • For searchers: the full abstract is reproduced below, so you can judge relevance before opening the publisher page.

Limitations & what to check in the full text

  • This brief is based on the published abstract only. Effect sizes, subgroup results and safety detail in the full text may qualify the headline findings.

Frequently asked questions

What did this European Heart Journal study find?

Similar patterns were observed across individual APOs.<h4>Conclusions</h4>Considering APO sequence across complete pregnancy histories provides more detailed CVD information than binary classification.

What type of study is this?

It is a cohort / observational clinical study, published in European Heart Journal in 2026. Hazard ratios (HRs) were estimated using Cox proportional hazards models.<h4>Results</h4>For composite APOs, women with APOs in first pregnancy and no further pregnancies had the highest CVD mortality [adjusted HR (aHR) 3.30, 95% confidence interval (CI) 2.97-3.66], followed by those with APOs in both first and later pregnancies (aHR 2.41, 95% CI 2.16-2.69).

Where can I read the original paper?

The original is at the publisher via DOI 10.1093/eurheartj/ehag564. PubMed ID: 42554048. BioStudioAI reproduces the abstract for discussion and links to the source.

How to cite the original: Singh A, Skjærven R, Wilcox AJ et al.. Adverse pregnancy outcomes in successive pregnancies and maternal cardiovascular mortality: a Norwegian nationwide study.. European Heart Journal (2026). DOI: 10.1093/eurheartj/ehag564.
This brief: BioStudioAI Journal Watch, 29 October 2026. https://biostudioai.com/blog/papers/adverse-pregnancy-outcomes-in-successive-pregnancies-and-maternal-cardio-hag564/

Reading papers is step one. Analysing the data is the work.

BioStudioAI turns raw lab files into QC'd results, statistics, figures, reports and slides — hosted on your servers, every number computed, nothing typed.

Open BioStudioAI More guides